huMAb OX40L

Phase 2Small molecule

Roche

huMAb OX40L is one of 35 small molecule programs targeting Airway obstruction. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Airway ObstructionActive, not recruiting

Airway ObstructionPhase 2

Active, not recruiting

Competition

Competitive Landscape

39 competitors in Airway Obstruction

#DrugCompanyPhaseTrials

Daliresp

Theo-Dur

Onbrez

Brethine

Kenalog

Adrenaline

SSamson Clinical Operations Pty Ltd

Approved

—7

Serevent

GGlaxo Dba Glaxosmithkline

Striverdi Respimat

Singulair

Pulmicort

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Airway obstruction1 trial

A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma

Completed· Roche logo

Roche·Phase 2·NCT00983658·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for huMAb OX40L. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — huMAb OX40L compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for huMAb OX40L. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Roche

huMAb OX40L

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Airway obstruction1 trial

References

Drug Info

Quick Facts

Related News